One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE
Long-term survival in the ALEX trial: a milestone in improving the prognosis of patients with ALK-positive non-small-cell lung cancer
Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC: Editorial on: The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study
Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer
Nivolumab and cabozantinib combination therapy demonstrates sustained efficacy in metastatic renal-cell carcinoma
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial☆
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)☆
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study☆
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274☆
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO☆
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study☆
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study☆
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer☆
Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA
